

Francesca Romana Ponziani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5231409/publications.pdf>

Version: 2024-02-01

101
papers

4,139
citations

109264

35
h-index

128225

60
g-index

102
all docs

102
docs citations

102
times ranked

5544
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 107-120.	3.6	433
2	Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development. <i>Journal of Hepatology</i> , 2009, 51, 682-689.	1.8	409
3	Portal vein thrombosis: Insight into physiopathology, diagnosis, and treatment. <i>World Journal of Gastroenterology</i> , 2010, 16, 143.	1.4	248
4	Liver Transplantation in Alcoholic Patients: Impact of an Alcohol Addiction Unit Within a Liver Transplant Center. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1601-1608.	1.4	156
5	Intestinal Barrier in Human Health and Disease. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12836.	1.2	129
6	Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. <i>World Journal of Gastroenterology</i> , 2017, 23, 4491.	1.4	118
7	The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. <i>Digestive Diseases</i> , 2016, 34, 269-278.	0.8	105
8	Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. <i>World Journal of Gastroenterology</i> , 2013, 19, 7515.	1.4	102
9	Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. <i>World Journal of Gastroenterology</i> , 2019, 25, 4814-4834.	1.4	101
10	Gut Microbial, Inflammatory and Metabolic Signatures in Older People with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study. <i>Nutrients</i> , 2020, 12, 65.	1.7	98
11	Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 641-656.	1.4	95
12	Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. <i>World Journal of Gastroenterology</i> , 2019, 25, 4360-4382.	1.4	83
13	Radial Artery as a Coronary Artery Bypass Conduit. <i>Journal of the American College of Cardiology</i> , 2016, 68, 603-610.	1.2	80
14	Physiology and pathophysiology of liver lipid metabolism. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1055-1067.	1.4	77
15	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2019, 51, 190-205.	0.4	77
16	Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2 positive patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1060-1068.	1.9	76
17	Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: The role of dynamic contrast enhanced ultrasound. <i>Journal of Hepatology</i> , 2013, 59, 1014-1021.	1.8	75
18	Use and indications of cholestyramine and bile acid sequestrants. <i>Internal and Emergency Medicine</i> , 2013, 8, 205-210.	1.0	75

#	ARTICLE	IF	CITATIONS
19	Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease. <i>Liver International</i> , 2020, 40, 878-888.	1.9	68
20	Portal vein thrombosis and liver transplantation: Implications for waiting list period, surgical approach, early and late follow-up. <i>Transplantation Reviews</i> , 2014, 28, 92-101.	1.2	67
21	Gut microbiota and metabolic syndrome. <i>Internal and Emergency Medicine</i> , 2013, 8, 11-15.	1.0	66
22	Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. <i>World Journal of Gastroenterology</i> , 2015, 21, 12322.	1.4	65
23	Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1301-1311.	1.9	63
24	Esophageal microbiome signature in patients with Barrett's esophagus and esophageal adenocarcinoma. <i>PLoS ONE</i> , 2020, 15, e0231789.	1.1	58
25	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. <i>Digestive and Liver Disease</i> , 2020, 52, 937-941.	0.4	53
26	Characterization of the gut-liver-muscle axis in cirrhotic patients with sarcopenia. <i>Liver International</i> , 2021, 41, 1320-1334.	1.9	51
27	Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. <i>World Journal of Hepatology</i> , 2017, 9, 352.	0.8	50
28	Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984818.	1.4	47
29	Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate. <i>World Journal of Gastroenterology</i> , 2019, 25, 4437-4451.	1.4	47
30	What we should know about portal vein thrombosis in cirrhotic patients: A changing perspective. <i>World Journal of Gastroenterology</i> , 2012, 18, 5014.	1.4	46
31	Prevention and treatment of hepatic encephalopathy: Focusing on gut microbiota. <i>World Journal of Gastroenterology</i> , 2012, 18, 6693.	1.4	46
32	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , 2019, 11, 1689.	1.7	44
33	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1105-1114.	0.4	41
34	Diagnosis and treatment of small intestinal bacterial overgrowth. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 215-227.	1.4	40
35	Sarcopenia in Patients with Advanced Liver Disease. <i>Current Protein and Peptide Science</i> , 2018, 19, 681-691.	0.7	40
36	Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. <i>Digestive and Liver Disease</i> , 2022, 54, 452-460.	0.4	38

#	ARTICLE	IF	CITATIONS
37	COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. <i>World Journal of Gastroenterology</i> , 2021, 27, 7433-7445.	1.4	37
38	Morphological and functional consequences of transradial coronary angiography on the radial artery: implications for its use as a bypass conduit. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 48, 370-374.	0.6	36
39	Gut Microbiota during Dietary Restrictions: New Insights in Non-Communicable Diseases. <i>Microorganisms</i> , 2020, 8, 1140.	1.6	35
40	Subclinical atherosclerosis is linked to small intestinal bacterial overgrowth via vitamin K2-dependent mechanisms. <i>World Journal of Gastroenterology</i> , 2017, 23, 1241.	1.4	33
41	Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 1033-1042.	1.9	28
42	Diagnosis of bowel diseases: The role of imaging and ultrasonography. <i>World Journal of Gastroenterology</i> , 2013, 19, 2144.	1.4	25
43	Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut-Liver Axis. <i>Nutrients</i> , 2021, 13, 2649.	1.7	24
44	Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment. <i>World Journal of Gastroenterology</i> , 2022, 28, 2251-2281.	1.4	23
45	Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2022, 6, 1492-1501.	2.0	22
46	Management of Hepatitis C Virus Infection Recurrence After Liver Transplantation: An Overview. <i>Transplantation Proceedings</i> , 2011, 43, 291-295.	0.3	21
47	Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 983-991.	1.0	18
48	Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort. <i>Digestive and Liver Disease</i> , 2015, 47, 689-694.	0.4	17
49	Regorafenib: a promising treatment for hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1941-1948.	0.9	17
50	Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. <i>Nutrients</i> , 2020, 12, 3101.	1.7	17
51	Contrast-enhanced ultrasound patterns of hepatocellular adenoma: an Italian multicenter experience. <i>Journal of Ultrasound</i> , 2019, 22, 157-165.	0.7	16
52	Congenital extrahepatic portosystemic shunt: description of four cases and review of the literature. <i>Journal of Ultrasound</i> , 2019, 22, 349-358.	0.7	15
53	Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports. <i>American Journal of Kidney Diseases</i> , 2017, 70, 297-300.	2.1	14
54	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , 2021, 53, 677-681.	0.4	13

#	ARTICLE	IF	CITATIONS
55	Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey. <i>Liver International</i> , 2021, 41, 2228-2232.	1.9	13
56	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14755.	0.8	13
57	Is there a role for anticoagulants in portal vein thrombosis management in cirrhotic patients?. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1479-1487.	0.9	12
58	Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 2605.	1.0	12
59	Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , 2021, 16, 1341-1356.	1.0	12
60	Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. <i>Transplant International</i> , 2012, 25, 448-454.	0.8	11
61	Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 993-995.	0.6	10
62	Improved gut microbiota features after the resolution of SARS-CoV-2 infection. <i>Gut Pathogens</i> , 2021, 13, 62.	1.6	10
63	Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 902-903.	1.9	9
64	Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 347-360.	1.9	9
65	Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible?. <i>European Journal of Radiology</i> , 2019, 114, 32-37.	1.2	8
66	Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation and in liver transplant recipients. <i>Digestive and Liver Disease</i> , 2021, 53, 1232-1234.	0.4	8
67	Thrombosis after liver transplantation for hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0186699.	1.1	8
68	The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1535-1546.	1.5	7
69	Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. <i>Transplant International</i> , 2013, 26, 281-289.	0.8	7
70	Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study. <i>Scientific Reports</i> , 2019, 9, 15373.	1.6	7
71	Effect of liver transplantation on intestinal permeability and correlation with infection episodes. <i>PLoS ONE</i> , 2020, 15, e0235359.	1.1	7
72	Contrast-Enhanced Ultrasound in the Short-Term Evaluation of Hepatocellular Carcinoma after Locoregional Treatment. <i>Digestive Diseases</i> , 2020, 38, 522-533.	0.8	7

#	ARTICLE	IF	CITATIONS
73	Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban. <i>Liver International</i> , 2017, 37, 1251-1251.	1.9	6
74	Treatment of early stage chronic hepatitis C virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 519-524.	1.3	6
75	Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1493-1500.	1.0	6
76	Correlation Between Liver Function Tests Abnormalities and Interleukin-6 Serum Levels in Patients With SARS-CoV-2 Infection. <i>Gastroenterology</i> , 2021, 160, 1891-1893.	0.6	6
77	Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2013, 19, 3255.	1.4	6
78	VIRAL CIRRHOSIS: AN OVERVIEW OF HAEMOSTATIC ALTERATIONS AND CLINICAL CONSEQUENCES. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009, 1, e2009033.	0.5	6
79	Risk factors for portal vein thrombosis or venous thromboembolism in a large cohort of hospitalized cirrhotic patients. <i>Internal and Emergency Medicine</i> , 2022, 17, 1327-1334.	1.0	6
80	Low molecular weight heparin as cause of liver injury: case report and literature review. <i>European Review for Medical and Pharmacological Sciences</i> , 2019, 23, 7649-7654.	0.5	6
81	Anticoagulants in Cirrhotic Patients: Controversies and Certainties in PVT Management. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2011, 9, 183-189.	0.4	5
82	Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project. <i>Journal of Viral Hepatitis</i> , 2021, 28, 651-656.	1.0	5
83	Advances in pharmacotherapeutics for hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1343-1354.	0.9	5
84	Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C group study. <i>Annals of Hepatology</i> , 2012, 11, 338-42.	0.6	5
85	Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time?. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2220-2222.	1.1	4
86	Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 440-445.	0.4	3
87	Letter: liver involvement and mortality in COVID-19 patients – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1264-1265.	1.9	3
88	Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 1005.	1.1	3
89	Going with the gut: probiotics as a novel therapy for hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 295-297.	0.7	2
90	NAFLD or comorbidities, that is the question. <i>Journal of Hepatology</i> , 2020, 73, 723.	1.8	2

#	ARTICLE	IF	CITATIONS
91	Reverse time-dependent effect of alfafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. World Journal of Hepatology, 2017, 9, 1322-1331.	0.8	2
92	Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients. Digestive and Liver Disease, 2021, 53, 541-544.	0.4	1
93	Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time?. Hepatology, 2021, 74, 1718-1718.	3.6	1
94	Diet-Induced Alterations in Gut Microbiota Composition and Function. , 2022, , .		1
95	How to modulate gut microbiota: diet, preprobiotics or antibiotics?. Minerva Gastroenterology, 2017, 63, 411-419.	0.3	1
96	Reply to Nezc. European Journal of Cardio-thoracic Surgery, 2016, 49, 1021.2-1022.	0.6	0
97	Bile Collection Detected With BrIDA Scintigraphy in a Patient With Hepatocellular Carcinoma. Clinical Nuclear Medicine, 2018, 43, 823-824.	0.7	0
98	Letter: improvement of clinical outcomes by metformin in metabolic liver diseaseâ€”a microbiotaâ€”dependent mechanism?. Alimentary Pharmacology and Therapeutics, 2019, 50, 474-474.	1.9	0
99	Editorial: Before and after Liver Transplantation. The Open Transplantation Journal, 2011, 5, 30-31.	0.1	0
100	Walking on the Molecular Pathway: m-TOR Inhibition in the Liver Transplant Setting. The Open Transplantation Journal, 2011, 5, 35-43.	0.1	0
101	Bridge Treatments for HCC in the Waiting List for Liver Transplantation. The Open Transplantation Journal, 2011, 5, 44-49.	0.1	0